NextCure, Inc.

NasdaqGS:NXTC Voorraadrapport

Marktkapitalisatie: US$37.2m

NextCure Beheer

Beheer criteriumcontroles 3/4

NextCure's CEO is Michael Richman, appointed in Oct 2015, has a tenure of 9.08 years. total yearly compensation is $1.04M, comprised of 54.7% salary and 45.3% bonuses, including company stock and options. directly owns 1.45% of the company’s shares, worth $540.41K. The average tenure of the management team and the board of directors is 5.1 years and 4.2 years respectively.

Belangrijke informatie

Michael Richman

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris54.7%
Dienstverband CEO9.1yrs
Eigendom CEO1.5%
Management gemiddelde ambtstermijn5.1yrs
Gemiddelde ambtstermijn bestuur4.2yrs

Recente managementupdates

Recent updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Jul 17
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Mar 23
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Dec 09
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Aug 23
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

May 10
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Nov 22
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Aug 09
Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

NextCure GAAP EPS of -$0.59

Aug 04

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

May 02
We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure: Large Upside With Downside Protected By Cash Pile

Sep 29

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12
Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08
NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure provides update on NC318 clinical program

Dec 17

Analyse CEO-vergoeding

Hoe is Michael Richman's beloning veranderd ten opzichte van NextCure's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$61m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$1mUS$572k

-US$63m

Sep 30 2023n/an/a

-US$66m

Jun 30 2023n/an/a

-US$70m

Mar 31 2023n/an/a

-US$70m

Dec 31 2022US$2mUS$549k

-US$75m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$529k

-US$69m

Sep 30 2021n/an/a

-US$68m

Jun 30 2021n/an/a

-US$66m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$6mUS$491k

-US$37m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$626kUS$419k

-US$34m

Sep 30 2019n/an/a

-US$30m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$24m

Dec 31 2018US$3mUS$383k

-US$23m

Compensatie versus markt: Michael's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Michael's compensation has been consistent with company performance over the past year.

CEO

Michael Richman (63 yo)

9.1yrs

Tenure

US$1,044,627

Compensatie

Mr. Michael S. Richman, MSBA, Co-founded NextCure, Inc. since 2015 and has been its Chief Executive Officer, President & Director since July 2015. Mr. Richman served as the Chief Executive Officer and Pres...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Michael Richman
Co-Founder9.1yrsUS$1.04m1.45%
$ 540.4k
Solomon Langermann
Chief Scientific Officer5.9yrsUS$681.59k0.13%
$ 49.7k
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Board9.8yrsgeen gegevensgeen gegevens
Steven Cobourn
Chief Financial Officer6.8yrsUS$1.01mgeen gegevens
Timothy Mayer
Chief Operating Officer5.1yrsgeen gegevensgeen gegevens
Kevin Shaw
Senior VP & General Counsel2.5yrsgeen gegevensgeen gegevens
Sourav Kundu
Senior Vice President of Development & Manufacturing3.3yrsgeen gegevensgeen gegevens
Sebastien Maloveste
Senior Vice President of Business Development1.3yrsgeen gegevensgeen gegevens
Udayan Guha
Senior Vice President of Clinical & Translational Development1.3yrsgeen gegevensgeen gegevens

5.1yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: NXTC's management team is seasoned and experienced (5.1 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Michael Richman
Co-Founder9.1yrsUS$1.04m1.45%
$ 540.4k
Lieping Chen
Co-Founder & Chairman of Scientific Advisory Boardno datageen gegevensgeen gegevens
Elaine Jones
Independent Director8.9yrsUS$67.47k0%
$ 0
Mario Sznol
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
David Kabakoff
Independent Chairman of the Board8.9yrsUS$93.16k0.22%
$ 82.8k
Stephen Webster
Independent Director5.6yrsUS$71.66k0%
$ 0
Ellen Feigal
Independent Director3.1yrsUS$61.66k0%
$ 0
Stephen Miller
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
John Houston
Independent Director4.2yrsUS$61.66k0%
$ 0
Weiping Zou
Member of Scientific Advisory Board3.1yrsgeen gegevensgeen gegevens
Ursula Matulonis
Member of Scientific Advisory Board3.1yrsgeen gegevensgeen gegevens
Anne Borgman-Hagey
Independent Director3.1yrsUS$60.66k0%
$ 0

4.2yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: NXTC's board of directors are considered experienced (4.2 years average tenure).